ONCONASDAQHealthcare· Biotechnology

Onconetix, Inc.

$0.11-6.38%($-0.01)
TickerSpark Score
57/100
Mixed
100
Valuation
40
Profitability
55
Growth
60
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ONCO research report →

52-Week Range0% of range
Low $0.09
Current $0.11
High $38.25

Companyonconetix.gcs-web.com

Onconetix, Inc. , a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia.

CEO
David Allan White
IPO
2022
Employees
12
HQ
Cincinnati, OH, US

Price Chart

-99.71% · this period
$37.40$18.75$0.11May 20Nov 18May 20

Valuation

Market Cap
$376.89K
P/E
-0.01
P/S
0.51
P/B
0.01
EV/EBITDA
0.45
Div Yield
0.00%

Profitability

Gross Margin
79.63%
Op Margin
-922.72%
Net Margin
-1319.55%
ROE
-105.46%
ROIC
-56.35%

Growth & Income

Revenue
$815.37K · -67.70%
Net Income
$-14,032,342 · 76.09%
EPS
$-4.73 · 99.09%
Op Income
$-6,344,856
FCF YoY
8.04%

Performance & Tape

52W High
$38.25
52W Low
$0.09
50D MA
$1.32
200D MA
$8.94
Beta
3.01
Avg Volume
10.30M

Get TickerSpark's AI analysis on ONCO

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Apr 21, 26HRT FINANCIAL LPsell49,710
Apr 17, 26HRT FINANCIAL LPbuy34,636
Apr 16, 26HRT FINANCIAL LPsell53,867
Apr 20, 26HRT FINANCIAL LPsell94,462
Apr 15, 26HRT FINANCIAL LPbuy92,554
Apr 14, 26HRT FINANCIAL LPbuy74,350
Apr 14, 26HRT FINANCIAL LPother0
Mar 18, 26White David Allanother0
Mar 19, 26DORF SAMMYother0
Dec 5, 25Romano Sarahother0

Our ONCO Coverage

We haven't published any research on ONCO yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate ONCO Report →

Similar Companies

JSPR+6.61%
Jasper Therapeutics, Inc.
$0.87
AZTR+3.68%
Azitra, Inc.
$0.20
REVB+5.83%
Revelation Biosciences, Inc.
$1.09
SCNI-6.02%
Scinai Immunotherapeutics Ltd.
$0.48
SPRC-9.89%
SciSparc Ltd.
$4.10
INDP-7.52%
Indaptus Therapeutics, Inc.
$1.23
ENVB+4.27%
Enveric Biosciences, Inc.
$2.20
SLXN+96.95%
Silexion Therapeutics Ltd.
$0.53